ABBVIE

Genmab achieved 21% revenue growth to $2.66 billion in the first nine months of 2025, driven primarily by increased DARZALEX and Kesimpta royalties.

Roche will present 46 abstracts including 12 oral presentations at the 67th ASH Annual Meeting, demonstrating progress across hemophilia A, lymphoma, and multiple myeloma treatments.

Alector's investigational antibody latozinemab failed to slow disease progression in a 96-week Phase III trial for frontotemporal dementia caused by progranulin gene mutations.

Merck KGaA's antibody-drug conjugate precemtabart tocentecan (Precem-TcT) demonstrated a 31% objective response rate in heavily pre-treated colorectal cancer patients at 2.8mg/kg dose during Phase I trials.

AbbVie's SELECT-SWITCH study marks the first Phase 3b/4 head-to-head trial comparing TNF inhibitor cycling with switching to JAK inhibitor upadacitinib in moderate to severe rheumatoid arthritis patients who failed initial TNF inhibitor therapy.

ADARx Pharmaceuticals will present initial Phase 1 clinical data for ADX-038, an investigational siRNA therapy targeting complement factor B, at the American Society of Nephrology Kidney Week meeting in Houston.

Calico Life Sciences, Alphabet's biotechnology subsidiary focused on aging research, has appointed Philip R. Kym, Ph.D., as its first Head of Drug Discovery in a newly created leadership position.

Enveric Biosciences has hired Fish and Richardson P.C. to defend its U.S. Patent No. 12,138,276 against a Post-Grant Review petition filed by Gilgamesh Pharmaceuticals.

The FDA approved an updated indication for RINVOQ (upadacitinib) allowing its use in IBD patients after one systemic therapy when TNF blockers are clinically inadvisable, expanding treatment options beyond the previous requirement for TNF blocker failure.

ResearchAndMarkets.com released a comprehensive report analyzing 1,775 clinical-stage partnering deals in pharma and biotech from 2020-2025, providing detailed financial terms and strategic insights.